Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
gyrLTG9NQJbsSzVb
Listen
